Clinical trials: Thyroid Cancer
Thyroid Cancer, Active Surveillance
Patients With a Single, Small (2 cm or Less) Cancer Nodule in the Thyroid Gland Will be Offered Active Surveillance Initially for 5 Years. In Case of Cancer Growth or Changes in Ultrasonographic Appearance, Further Treatment Will be Offered.
Patients with a single, small (less than 2 cm) cancer nodule in the thyroid gland will be offered active surveillance initially for 5 years.
- Trial name
- NCT07822217
- Where
- Denmark
- Volunteers
- 90 people
- Sponsor
- University of Aarhus
Thyroid Surgery, Electrical Stimulation
The Application of Electrical Stimulation in Postoperative Pain Management of Thyroid Surgery
Post-thyroidectomy pain is a prevalent early postoperative complication. While pharmacological agents remain the mainstay of analgesia, their clinical application is constrained by adverse effects including nausea, respiratory…
- Conditions
- Thyroid Surgery, Electrical Stimulation, Thyroid Carcinoma
- Trial name
- NCT06931743
- Testing
- CMNS6-1 Electronic Acupuncture Therapeutic Apparatus
- Where
- 3 sites in China
- Volunteers
- 668 people
- Sponsor
- Xiaonan Huang
Quality of Life
A Follow-up Study on Total Endoscopic Thyroidectomy Bilateral Areola Approach
Endoscopic thyroidectomy bilateral areola approach (ETBAA) is one of the most widely applied approach in China, meanwhile its safety and effectiveness has been broadly discussed since being introduced.
- Trial name
- NCT05315219
- Testing
- Endoscopic Thyroidectomy Bilateral Areola Approach
- Volunteers
- 295 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Neoplasm Metastasis
Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors
The CC-90003-ST -001 trial is a first-in-man, open-label study in subjects with locally-advanced or wide spread cancers to determine if CC-90003 (an oral medication) can be adequately tolerated with minimal side effects.
- Trial name
- NCT02313012
- Testing
- CC-90003
- Where
- 5 sites in United States, Australia
- Volunteers
- 19 people
- Sponsor
- Celgene
Thyroid Cancer, Breast Cancer
The Incidence of Breast and Other Cancers Among Female Flight Attendants
Flight attendants may be at an increased risk of breast and other cancers due to work-place exposures including cosmic radiation and circadian rhythm disruption form traveling across multiple time zones.
- Conditions
- Thyroid Cancer, Breast Cancer, Non-Melanoma Skin Cancer, Melanoma
- Trial name
- NCT00342407
- Where
- United States
- Volunteers
- 6,093 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Colorectal Cancer
Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer
RATIONALE: Vaccines made from a person's white blood cells that have been treated in the laboratory may make the body build an immune response to kill tumor cells.
- Conditions
- Breast Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer
- Trial name
- NCT00027534
- Testing
- TRICOM-CEA(6D)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Michael Morse, MD
Thyroid Cancer, Papillary
Intraoperative Pathologic Evaluation of Central Lymph Nodes in Papillary Thyroid Carcinoma
Efficacy of Intraoperative pathologic evaluation of central lymph nodes
- Trial name
- NCT07066644
- Testing
- central node dissection
- Where
- South Korea
- Volunteers
- 509 people
- Sponsor
- Seoul National University Hospital
Cancer, Tumor, Solid
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced…
- Conditions
- Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer
- Trial name
- NCT05620134
- Testing
- JK08, Pembrolizumab, Lenvatinib Pill
- Where
- 11 sites in Belgium, Spain
- Volunteers
- 263 people
- Sponsor
- Salubris Biotherapeutics Inc
Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma
Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer
This study aims to observe and explore the efficacy and safety of Anlotinib combined with penpulimab in the treatment of radioiodine refractory differentiated thyroid cancer with first-line resistance to angiogenesis inhibitors…
- Trial name
- NCT06062563
- Testing
- Anlotinib Hydrochloride Capsule and Penpulimab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Peking Union Medical College Hospital
Differentiated Thyroid Cancer
Reinducing Radioiodine-sensitivity in Radioiodine-refractory DTC Using Lenvatinib (RESET)
This is a single-centre open label phase II study evaluating the effect of lenvatinib treatment for restoring radioiodine uptake and retention in radioiodine-refractory (RAI-R) thyroid cancer to warrant I-131 therapy.
- Trial name
- RESET (NCT04858867)
- Testing
- rhTSH-stimulated I-124 dosimetry, Intra-therapeutic I-131 dosimetry
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Leiden University Medical Center
Metastatic Thyroid Papillary Carcinoma, Metastatic Thyroid Follicular Carcinoma
Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial
This is a prospective, multi-centre, open label, stratified, exploratory phase II study evaluating the efficacy and safety of durvalumab plus tremelimumab in different cohorts of patients with thyroid cancers.
- Conditions
- Metastatic Thyroid Papillary Carcinoma, Metastatic Thyroid Follicular Carcinoma, Metastatic Thyroid Cancer
- Trial name
- DUTHY (NCT03753919)
- Testing
- Durvalumab, Tremelimumab
- Where
- 15 sites in Spain
- Volunteers
- 79 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Malignant Neoplasm of Bone and Articular Cartilage, Malignant Neoplasms of Female Genital Organs
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to find the highest tolerable dose of gemcitabine that can be given by…
- Conditions
- Malignant Neoplasm of Bone and Articular Cartilage, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Independent (Primary) Multiple Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx
- Trial name
- NCT03093909
- Testing
- Gemcitabine
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- M.D. Anderson Cancer Center
Papillary Thyroid Carcinoma
Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436
Radioactive iodine therapy is often part of the standard treatment for Papillary Thyroid Carcinoma (PTC) patients. However, in many patients, tumors develop a resistance or no longer respond to radioactive iodine therapy…
- Trial name
- NCT01534897
- Testing
- GSK2118436
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Breast Cancer, Cancer
IIT2020-20-SHIRAZIP-WALK: Nature Walks
The purpose of this study is to examine whether nature-based activities provide benefits for breast cancer survivors. The investigators want to know whether a nature-based exercise program is feasible.
- Conditions
- Breast Cancer, Cancer, Lymphoma, Leukemia
- Trial name
- NCT04896580
- Testing
- Nature based exercise
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Cancer, BRAF V600 Mutation
XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation
This is a first-in-human multi-center study which will be conducted in advanced malignant solid tumors patients. The solid tumor type is limited to melanoma, colorectal, non-small-cell lung, and thyroid cancer with positive BRAF…
- Conditions
- Cancer, BRAF V600 Mutation, Melanoma, Colorectal Cancer
- Trial name
- ENHANCE (NCT05275374)
- Testing
- XP-102, Trametinib
- Volunteers
- 221 people
- Sponsor
- Xynomic Pharmaceuticals, Inc.
Thyroid Carcinoma
A Study Into the Effect of Seprafilm in Open Total Thyroidectomy
The investigators intend to determine the role of Seprafilm, a popular anti-adhesive agent in minimising internal adhesion formation in the neck after thyroid surgery and therefore reduce swallowing discomfort experienced by…
- Trial name
- NCT01865838
- Testing
- Seprafilm (Sanofi, USA)
- Where
- 2 sites in Singapore
- Volunteers
- 19 people
- Sponsor
- National Cancer Centre, Singapore
Thyroid Cancer
Myeloid Cell Reprogramming in Thyroid Carcinoma
This study investigates the reprogramming of myeloid cells in patients with thyroid carcinoma. The investigators hypothesize that tumor-derived factors change the function of myeloid cells (peripheral blood and bone…
- Trial name
- NCT03397238
- Where
- Netherlands
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Thyroid Cancer
Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer
To compare the hypothyroid state in patients with thyroid cancer prepared either by placebo or L-T3 following L-T4 withdrawal in preparation for whole body scintigraphy.
- Trial name
- NCT00223158
- Testing
- Liothyronine
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Patrice Perron
Papillary Thyroid Cancer, Follicular Thyroid Cancer
Sutent Adjunctive Treatment of Differentiated Thyroid Cancer
This study is comparing a drug called Sutent with standard of care treatment for people with advanced thyroid cancer. Because advanced thyroid cancer is becoming increasingly common and effective treatment options are limited…
- Conditions
- Papillary Thyroid Cancer, Follicular Thyroid Cancer, Differentiated Thyroid Cancer
- Trial name
- IIT Sutent (NCT00668811)
- Testing
- SU011248, Sutent
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Medstar Health Research Institute
Parathyroid Neoplasms
Using X-Ray Dye to Locate Hidden Parathyroid Tumors
Occasionally tumors of the parathyroid gland cannot be detected by standard x-ray diagnostic procedures (CT scans, MRIs, and ultrasounds). In order for the tumor to be removed surgically it must first be localized.
- Trial name
- NCT00001394
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)